S-1 and Cisplatin Before Surgery in Treating Patients With Stage IV Gastric Cancer
Recruitment status was Active, not recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Drugs used in chemotherapy, such as S-1 and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Giving combination chemotherapy before surgery may shrink the tumor so that it can be removed.
PURPOSE: This phase II trial is studying how well giving S-1 together with cisplatin works in treating patients who are undergoing surgery for stage IV gastric cancer.
| Condition | Intervention | Phase |
|---|---|---|
|
Gastric Cancer |
Drug: cisplatin Drug: tegafur-gimeracil-oteracil potassium Procedure: adjuvant therapy Procedure: conventional surgery Procedure: neoadjuvant therapy |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Phase II Clinical Study of Preoperative S-1/CDDP Combination Chemotherapy in Patients With Advanced Gastric Cancer |
- Overall survival [ Designated as safety issue: No ]
- Time to progression [ Designated as safety issue: No ]
- Tumor response [ Designated as safety issue: No ]
- Death related to treatment [ Designated as safety issue: No ]
- Histological response [ Designated as safety issue: No ]
- Postoperative complications [ Designated as safety issue: No ]
- Surgical/pathological curative resection [ Designated as safety issue: No ]
- Types of initial recurrence [ Designated as safety issue: No ]
- Adverse events [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 50 |
| Study Start Date: | April 2003 |
| Estimated Primary Completion Date: | March 2008 (Final data collection date for primary outcome measure) |
OBJECTIVES:
Primary
- Determine the efficacy and feasibility of neoadjuvant chemotherapy comprising S-1 and cisplatin in patients with stage IV gastric adenocarcinoma.
- Determine the overall survival of patients treated with this regimen.
Secondary
- Determine the time to progression and types of initial recurrence in patients treated with this regimen.
- Determine tumor response in patients treated with this regimen.
- Determine mortality and morbidity related to treatment in these patients.
- Determine the toxicity of this regimen in these patients.
OUTLINE: This is a multicenter study.
Patients receive oral S-1 on days 1-21 and cisplatin IV over 2 hours on day 8. Treatment repeats every 35 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo gastrectomy with lymphadenectomy. Patients resume oral S-1 after surgery.
PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.
Eligibility| Ages Eligible for Study: | 20 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically confirmed gastric adenocarcinoma
Stage IV disease meeting 1 of the following staging criteria according to Japanese gastric cancer classification:
- T4, N2
- T4, N3
- P1, CY1
- CT scan and laparoscopic staging required
PATIENT CHARACTERISTICS:
Age
- 20 and over
Performance status
- ECOG 0-1
Life expectancy
- Not specified
Hematopoietic
- WBC ≥ 4,000/mm^3 AND < 12,000/mm^3
- Granulocyte count ≥ 2,000/mm^3
- Platelet count ≥ 100,000/mm^3
- Hemoglobin ≥ 9.0 g/dL
Hepatic
- AST and ALT ≤ 2.5 times upper limit of normal
- Bilirubin ≤ 1.5 mg/dL
Renal
- Creatinine clearance ≥ 50 mL/min
Pulmonary
- PaO_2 ≥ 70 mm Hg on room air
Other
- Able to swallow oral medication
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- No prior chemotherapy for gastric cancer
Endocrine therapy
- Not specified
Radiotherapy
- No prior radiotherapy for gastric cancer
Surgery
- No prior surgery for gastric cancer
Other
- No other prior therapy for gastric cancer
Contacts and Locations| Japan | |
| Shimane Prefectural Central Hospital | |
| Izumo-shi, Shimane, Japan, 693-0068 | |
| Kyoto University Hospital | |
| Kyoto, Japan, 606-8507 | |
| Kyoto-Katsura Hospital | |
| Kyoto, Japan, 615-8256 | |
| National Hospital Organization - Kyoto Medical Center | |
| Kyoto, Japan, 612-0861 | |
| Kansai Denryoku Hospital | |
| Osaka, Japan, 553-0003 | |
| Kitano Hospital | |
| Osaka, Japan, 530-8480 | |
| Yamato Municipal Hospital | |
| Yamato City Kanagawa, Japan, 242-8602 | |
| Study Chair: | Seiji Satoh | Kyoto University |
More Information
Additional Information:
No publications provided
| ClinicalTrials.gov Identifier: | NCT00088816 History of Changes |
| Other Study ID Numbers: | CDR0000368443, KYUH-UHA-GC03-01 |
| Study First Received: | August 4, 2004 |
| Last Updated: | October 30, 2010 |
| Health Authority: | United States: Federal Government |
Keywords provided by National Cancer Institute (NCI):
|
stage IV gastric cancer adenocarcinoma of the stomach |
Additional relevant MeSH terms:
|
Stomach Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Stomach Diseases S 1 (combination) Cisplatin |
Tegafur Antineoplastic Agents Therapeutic Uses Pharmacologic Actions Radiation-Sensitizing Agents Physiological Effects of Drugs Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on June 18, 2013